Esperion Therapeutics Inc (NASDAQ:ESPR) price on current trading day, fall -4.62% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.65.
A look at the stock’s price movement, the close in the last trading session was $1.73. Turning to its 52-week performance, $3.94 and $1.58 were the 52-week high and 52-week low respectively. Overall, ESPR moved -17.09% over the past month.
Esperion Therapeutics Inc’s market cap currently stands at around $325.11 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 61.58M for the company’s revenue for the quarter, with a low and high estimate of 46M and 79M respectively. The average forecast suggests up to a 90.96% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 324.73M, representing a 179.14% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ESPR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend ESPR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ESPR’s current price about -10.03% and -20.04% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 29.26, while 7-day volatility ratio is 5.77% and 5.52% in the 30-day chart. Further, Esperion Therapeutics Inc (ESPR) has a beta value of 1.04, and an average true range (ATR) of 0.12. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $8 and high of $8. Looking at the price targets, the low is -384.85% off current price level while to achieve the yearly target high, price needs to move -384.85%. Nonetheless, investors will most likely welcome a -384.85% jump to $8 which is the analysts’ median price.
If we refocus on Esperion Therapeutics Inc (NASDAQ:ESPR), historical trading data shows that trading volumes averaged 5.68 million over the past 3 months. The company’s latest data on shares outstanding shows there are 195.44 million shares.
The 0.99% of Esperion Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 66.15% of the company’s shares. Current price change has pushed the stock -25.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ESPR stock continues to rise going into the next quarter.
